Hadassah

Complex, Less Debilitating Treatment for Neuroendocrine Cancer Now Available in Israel at Hadassah

Wednesday, Feb 15 2012

A treatment for neuroendocrine cancer that was previously only available abroad is now being provided at the Hadassah University Medical Center. Patients are injected with radioactive material that attaches to the malignant cell, absorbing and destroying it with minimal damage to other tissue. The new treatment is the outgrowth of three years of collaboration between Hadassah and Israel's Soreq Nuclear Research Center, an applied research and development institute affiliated with the Israel Atomic Energy Commission. The radioactive material is assembled at the Soreq Center and sent to Hadassah once a week at a set time.

Based on the fact that these endocrine tumors have an increased ability to absorb a hormone called somatostatin, the therapeutic procedure involves attaching a similar molecule to the hormone which is, in turn, attached to a radioactive atom. The atom binds to receptors on the outer membrane of the tumor and is absorbed into the malignant cell, emitting ionizing radiation which destroys it.

According to Dr. Asher Salmon, Senior Oncologist at Hadassah's Sharett Institute of Oncology, the treatment successfully prolongs life expectancy for 80 percent of patients and retards the progress of the disease for 50 percent. "This treatment, considered one of the best and most innovative available, differs from chemotherapy, providing prolonged relief for the patients with only a few side effects," he says. Following just one day in the hospital, patients are sent home; within several days, they can resume their normal lives.

Hadassah's departments of endocrinology, oncology, nuclear medicine, and radiology collaborate in providing this treatment to Hadassah's patients.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Feb 14 2018

Student with MS Running the Jerusalem Marathon to Support Hadassah’s MS Program

Thanks to his physicians at the Hadassah Medical Center, Dov Guggenheim, who was diagnosed with Multiple Sclerosis (MS) in 2015, has gone from “depressed to optimistic, paralyzed to athletic, and, most important, hopeless to hopeful.”

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Texas Tropical Disease Expert Meets with Hadassah Infectious Disease Specialists

Dr. Peter Jay Hotez, renowned professor in the Departments of Pediatrics and Molecular Virology and Microbiology at Houston (Texas) Baylor College of Medicine and Dean of its National School of Tropical Medicine, met with two Hadassah Medical Organization infectious disease specialists to discuss regional cooperation in fighting tropical diseases, such as the now-infamous Zika virus and leishmaniosis, which is contracted from sand flies.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Large Hadassah Study Identifies Predictor of Greater Risk of End-Stage Renal Disease

The findings of a nationwide study of over a million and a half Israeli adolescents, conducted by researchers at the Hadassah-Hebrew University Braun School of Public Health and Community Medicine, suggest that kidney disease in childhood is associated with a significantly increased risk of end-stage renal disease (ESRD) in adulthood, even if kidney function seems normal in adolescence.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Israeli Start-up’s Algorithm Predicts Which Diabetic Patients Will Suffer Kidney Dysfunction Within One Year

The Israeli start-up Medial EarlySign has created a machine-learning-based model that has proven to identify diabetic patients who are at the highest risk for experiencing renal dysfunction within one year.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More